Metis Global Partners LLC Purchases 1,511 Shares of Zoetis Inc. (NYSE:ZTS)

Metis Global Partners LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 4.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 32,187 shares of the company’s stock after purchasing an additional 1,511 shares during the period. Metis Global Partners LLC’s holdings in Zoetis were worth $6,289,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. First Personal Financial Services bought a new position in shares of Zoetis in the third quarter worth about $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis in the 3rd quarter valued at $33,000. Quarry LP increased its position in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares in the last quarter. Fortitude Family Office LLC lifted its stake in shares of Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after buying an additional 222 shares in the last quarter. Finally, LRI Investments LLC acquired a new stake in shares of Zoetis during the 1st quarter worth about $43,000. 92.80% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ZTS shares. Stifel Nicolaus boosted their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. BTIG Research upped their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. upped their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $221.44.

Zoetis Trading Up 1.9 %

Zoetis stock opened at $177.28 on Thursday. The business’s fifty day moving average is $187.61 and its 200 day moving average is $180.02. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The stock has a market capitalization of $79.98 billion, a PE ratio of 33.32, a price-to-earnings-growth ratio of 2.67 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.36 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be paid a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 0.97%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.